Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2017 April;152(2) > Giornale Italiano di Dermatologia e Venereologia 2017 April;152(2):126-31

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

ORIGINAL ARTICLE  


Giornale Italiano di Dermatologia e Venereologia 2017 April;152(2):126-31

DOI: 10.23736/S0392-0488.16.05187-7

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Melanocytic nevus count and dermoscopic features do not differ in psoriatic patients undergoing biological agent versus conventional drug therapy

Serpil PİRMİT 1, Nahide ONSUN 2, Ozlem SU 2, Dilek B. OZKAYA 2

1 Dermatology and Venereology Unit, Lepra Deri ve Zührevi Hastalıklar Hospital, İstanbul, Turkey; 2 Department of Dermatology and Venereology, Faculty of Medicine, Bezmialem Vakif University Hospital, İstanbul, Turkey


PDF  


BACKGROUND: Psoriasis is a chronic immune-mediated disease and treatment of psoriasis includes conventional immunosuppressive agents and biological agents. There are a few data on the relationship between psoriasis and melanocytic lesions. Either benign or malignant proliferations may be seen with immunosuppressive treatment. Eruptive nevi and malignant melanoma (MM) have been reported also associated with biological agents There is raising link biological treatment and malignancies. The objective of this paper is to examine the effects of biological agents versus conventional drugs on melanocytic nevi count and dermoscopical features.
METHODS: Sixty-seven patients receiving TNF-α antagonists (etanercept, infliximab and adalimumab) and 62 patients receiving methotrexate and cyclosporin included to the trial. Duration of treatment with biological agents ranged from 6 months to 4 years, and between 6 months to 3 years for conventional drugs. Total and regional nevi count and structurel changes of biological treatment was evaluated. All melanocytic lesions checked for dermoscopic features by using Dermogenius Ultra (Linos Photonics GmbH & Co, Munich, Germany). Diagnosis of atypical nevi and doubtful lesions for melanoma was made by using ABCD clinically and, by three point check list (asymmetry, atypical pigment network and blue whitish structures) dermoscopically.
RESULTS: There were no significant changes in number of total and regional nevi count and in the dermoscopic features of nevi between biological and conventional treatment groups. We observed dermoscopical changes in only one nevus of a patient receiving etanercept. Histopathological examination of this nevi confirmed the diagnosis of dysplastic nevi. There were no MM and non-melanoma skin cancers in both groups.
CONCLUSIONS: We did not observe significant changes in biological and conventional treatment groups there is a need for further studies to determine long-term effects of biological agents on the melanocytic lesions in patients with psoriasis.


KEY WORDS: Psoriasis - Nevus, pigmented - Melanoma

top of page

Publication History

Issue published online: February 1, 2017
Manuscript accepted: March 8, 2016
Manuscript revised: March 1, 2016
Manuscript received: July 29, 2016

Cite this article as

Pirmit S, Onsun N, Su O, Ozkaya DB. Melanocytic nevus count and dermoscopic features do not differ in psoriatic patients undergoing biological agent versus conventional drug therapy. G Ital Dermatol Venereol 2017;152:126-31. DOI: 10.23736/S0392-0488.16.05187-7

Corresponding author e-mail

serpilpirmit@gmail.com